Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ABT Abbott Laboratories
109.950-1.120-1.01%
Close
01/27 16:00 ET
109.9500.0000.00%
Post Mkt Price 01/27 19:01 ET
High
111.260
Open
110.650
Turnover
536.09M
Low
109.810
Pre Close
111.070
Volume
4.86M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Mount Yale Investment Advisors LLC Sells 7,208 Shares of Abbott Laboratories (NYSE:ABT)
Mount Yale Investment Advisors LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT – Get Rating) by 30.6% during the third quarter, according to the company in its most recent Form 1
Abbott Laboratories (NYSE:ABT) Updates FY23 Earnings Guidance
Abbott Laboratories (NYSE:ABT – Get Rating) updated its FY23 earnings guidance on Wednesday. The company provided earnings per share guidance of $4.30-4.50 for the period, compared to the consensus e
Is Abbott Laboratories a Good Dividend Stock to Buy Now?
Research Analysts Issue Forecasts for Abbott Laboratories' Q1 2023 Earnings (NYSE:ABT)
Abbott Laboratories (NYSE:ABT – Get Rating) – William Blair cut their Q1 2023 EPS estimates for shares of Abbott Laboratories in a report released on Thursday, January 26th. William Blair analyst
Abbott Labs (ABT) Gets a Buy From RBC Capital
Abbott Laboratories Stock Underperforms Friday When Compared To Competitors
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Abbott Laboratories (ABT) slid 1.01% to $109.95 Friday, on what proved to be an all-around
Abbott Laboratories (NYSE:ABT) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS
Abbott Laboratories (NYSE:ABT – Get Rating) released its quarterly earnings data on Wednesday. The healthcare product maker reported $1.03 earnings per share (EPS) for the quarter, beating the consen
Abbott Labs Price Target Raised to $125.00/Share From $122.00 by Barclays
Abbott Labs Is Maintained at Overweight by Barclays
Abbott Labs Is Maintained at Overweight by Barclays
Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $125
Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $122 to $125.
Company Overview
More
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1900 and is headquartered in Abbott Park, IL.
CEO： Mr. Robert B. Ford
Market： NYSE
Listing Date： 01/01/1929
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet